Abstract
Computed tomography has been introduced as a noninvasive imaging modality used for coronary artery calcium scoring in asymptomatic individuals and contrast-enhanced coronary angiography in symptomatic individuals. As the rising costs of healthcare reflect, in part, the development of these types of new expensive technologies for cardiac diagnosis, the economic considerations that surround them should be of interest to clinicians and payers alike. In this review, we discuss basic principles underlying economic efficiency analyses of medical products, using computed tomography in coronary artery disease as a case in point.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.